Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study

Trial Profile

Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Phenprocoumon
  • Indications Atrial fibrillation; Stroke; Thrombosis; Venous thromboembolism
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 29 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Sep 2014 according to ClinicalTrials.gov record.
    • 04 Aug 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Sep 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top